

## Medicis Pharmaceutical

[View the current Medicis Pharmaceutical Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/6845-Medicis+Pharmaceutical.html)

(<http://www.bioportfolio.com/biocorporate/6845-Medicis+Pharmaceutical.html>)

### Contact Details:

**8125 North Hayden Road**  
**Scottsdale**  
**AZ**  
**85258-2463**  
**United States of America**

Tel: (602) 808-8800  
Fax: (602) 808-0822  
Email: [customer\\_service@medicis.com](mailto:customer_service@medicis.com)

Medicis is a leading specialty pharmaceutical company focusing primarily on developing and marketing drugs in the U.S. for the treatment of dermatological, pediatric and podiatric conditions. Medicis offers a broad range of drugs addressing various conditions including acne, fungal infections, asthma, rosacea, hyperpigmentation, photoaging, psoriasis, eczema, skin and skin-structure infections, seborrheic dermatitis, head lice and cosmesis (improvement in the texture and appearance of skin).

Our focused attention on the primary functions of our business causes us to concentrate over 75% of our workforce in the sales, marketing and research & development divisions of the Company.

New product developments, internal growth, acquisitions and strategic collaborations have driven the success and expansion of the Company. Over the last five fiscal years, Medicis averaged a 50% annual sales growth and the Company has completed over eight consecutive profitable years.

With a balanced business in North America and an extraordinary track record of revenue, operating income growth and impressive gross profit margins, Medicis is driven to continue its success and assure long-term shareholder value.

### Recent Publications by Medicis Pharmaceutical:



- [Key bioavailability features of a new extended-release formulation of minocycline hydrochloride tablets.](#)  
*For a long time, minocycline has been recognized as highly efficacious for...* 12th May, 2007  
Medicis Pharmaceutical Corporation, Scottsdale, Arizona, USA.- *Cutis.* 2006 Oct;78(4 Suppl):6-10.
- [Evaluation of in vitro activity of ciclopirox olamine, butenafine HCl and econazole nitrate against dermatophytes, yeasts and bacteria.](#)  
*BACKGROUND: In many instances, a cutaneous fungal infection may exist...* 31st January, 2004  
Medicis Pharmaceutical Corporation, Scottsdale, AZ 85258, USA.- *Int J Dermatol.* 2003 Sep;42 Suppl 1:11-7.

## Press Releases on Medicis Pharmaceutical:

<a href="#">Frost &amp; Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market</a>	26th November, 2009	Frost & Sullivan	JOHANNESBURG, South Africa, Nov. 26 /PRNewswire/ -- The 2009 Frost & Sullivan South Africa Company of the Year Award in the Generic Pharmaceutical Market is presented to Cipla Medpro South Africa
<a href="#">Heska Announces Supply Agreement With Roche Diagnostics</a>	25th November, 2009	Heska Corporation	LOVELAND, Colo., Nov. 25 /PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq: HSKA); ("Heska"), a leading provider of advanced diagnostic and specialty products to the veterinary industry, HARBIN, China, Nov. 25 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated
<a href="#">China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits</a>	25th November, 2009	China Sky One Medical, Inc.	WOODCLIFF LAKE, N.J., Nov. 25 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced the results of its "Modified Dutch Auction" tender offer, in which Par DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals' service division and Pyxis Discovery announced today that they have signed a collaborative agreement
<a href="#">Par Pharmaceutical Announces Results of Its 'Modified Dutch Auction' Tender Offer</a>	25th November, 2009	Par Pharmaceutical Companies, Inc.	
<a href="#">iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering</a>	25th November, 2009		

## BioNews Results for Medicis Pharmaceutical



- [Biotech Stocks: Senate bill weighs on Allergan, Medicis](#)  
*MarketWatch: Nov 19 2009 9:20PM Matching: medicis pharmaceutical*
- [Senate bill weighs on Allergan, Medicis](#)  
*MarketWatch: Nov 19 2009 4:47PM Matching: medicis pharmaceutical*
- [Medicis Pharmaceutical \(MRX\) NewsBite - MRX Upgraded By Piper Jaffray](#)  
*Market Intelligence Center: Nov 18 2009 3:05AM Matching: medicis pharmaceutical*
- [Medicis Pharmaceutical \(MRX\) NewsBite - MRX Upgraded By Piper Jaf...](#)  
*Zibb: Nov 17 2009 8:45PM Matching: medicis pharmaceutical*
- [Glenmark Generics settles patent litigations with Medicis Pharmaceutical for Fluocinonide and](#)

## [Ciclopirox Olami](#)

TradingMarkets: Nov 17 2009 6:54PM Matching: *medicis pharmaceutical*

- [Piper Jaffray Upgrades Medicis Pharmaceutical \(MRX\) to Neutral; Gaining More Confidence](#)

Street Insider: Nov 17 2009 1:04PM Matching: *medicis pharmaceutical*

- [Analyst Upgrades for November 17th - Zibb.com](#)

Zibb: Nov 17 2009 3:00PM Matching: *medicis pharmaceutical*

- [Glenmark settles patent dispute with Medicis](#)

Individual.com: Nov 17 2009 9:52AM Matching: *medicis pharmaceutical*

- [Glenmark Generics settles Para IV litigations with Medicis Pharmaceutical Corporation](#)

Equity Bulls: Nov 16 2009 7:44AM Matching: *medicis pharmaceutical*

- [Glenmark Pharma outlicenses a specialty pharmaceutical product to Medicis Pharmaceutical for the North America](#)

Equity Bulls: Nov 16 2009 7:44AM Matching: *medicis pharmaceutical*

- [Glenmark settles patent dispute with Medicis](#)

Financial Express: Nov 16 2009 12:11PM Matching: *medicis pharmaceutical*

- [Glenmark Generics settles litigation with Medicis Pharma](#)

Yahoo! India: Nov 16 2009 6:14AM Matching: *medicis pharmaceutical*

- [Glenmark Generics settles litigation with Medicis Pharma](#)

Moneycontrol.com: Nov 16 2009 3:36PM Matching: *medicis pharmaceutical*

- [Glenmark gets anti-fungal drug OK, settles dispute with Medicis](#)

SmartBrief: Nov 16 2009 4:11PM Matching: *medicis pharmaceutical*

- [Glenmark settles patent cases with Medicis Pharma](#)

Hindu Business Line: Nov 16 2009 9:56PM Matching: *medicis pharmaceutical*

## Medicis Pharmaceutical Clinical Trials:



- [A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.](#)

## Medicis Pharmaceutical Patents:



- 7544373- [Minocycline oral dosage forms for the treatment of acne](#)
- 5648389- [Compositions for the treatment of dermatological disorders and methods for their use](#)
- 5932612- [Compositions and systems for the treatment of hyperpigmentation](#)
- 6514489- [Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions](#)
- 6586473- [Topical drug delivery composition and method](#)

- 6765001- [Compositions and methods for enhancing corticosteroid delivery](#)
- 6787160- [Compositions and methods for high sorption of skin materials and delivery of sulfur](#)
- 6855342- [Compositions and methods for high sorption of skin materials and delivery of sulfur](#)
- 6905675- [Sulfur containing dermatological compositions and methods for reducing malodors in dermatological compositions](#)
- 6955825- [Compositions and methods for high sorption of skin materials and delivery of sulfur](#)
- 6998130- [Compositions for the treatment of pigmentation disorders and methods for their manufacture](#)
- 7025977- [Compositions for the treatment of pigmentation disorders and methods for their manufacture](#)
- 7189759- [Compositions for the treatment of pigmentation disorders and methods for their manufacture](#)
- 7217422- [Compositions and methods for enhancing corticosteroid delivery](#)
- 7220424- [Compositions and methods for enhancing corticosteroid delivery](#)
- 7479289- [Stable cleanser compositions containing sulfur](#)
- 7541347- [Minocycline oral dosage forms for the treatment of acne](#)
- 5336692- [Ointment base and method of use](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

